GLP-1 companion

Losing weight on a GLP-1?
Look after your gut and liver too.

Daily GLP-1 Companion · a probiotic built for the Ozempic era

Ozempic, Wegovy and Mounjaro are changing lives — but rapid weight loss can be hard on your gut and asks a lot of your liver. We're building a next-generation probiotic companion, headed for clinical trial, designed to support gut comfort and the gut–liver axis while your medication does its work. Built by scientists and doctors.

$49.50 / month estimated · no payment taken today
Thanks — you're on the list. We'll be in touch as we get closer. ✓

No payment taken · grounded in peer-reviewed research · clinical trial planned · not a substitute for your medication

Coming soon Daily GLP-1 Companion — a daily probiotic for people on GLP-1 medications

Is a gut & liver companion right for you? A 30-second check

A few quick questions about your GLP-1 journey. This is educational only — always talk to your prescriber about your treatment.

Are you currently on a GLP-1 (Ozempic, Wegovy, Mounjaro, Zepbound)?
About to start one, or recently increased your dose?
Dealing with nausea, constipation or bloating?
Worried about losing muscle as well as fat?
Been told you have (or are at risk of) fatty liver?
Want to protect your gut health while you lose weight?

We'll email a plain-English summary and let you know when our clinical trial and early-access program open. No spam.

Thanks — check your inbox. You're on the early list. ✓

Millions are on a GLP-1. Almost no one is looking after the gut and liver alongside it.

GLP-1 medications work with a hormone your gut already makes. But rapid weight loss can bring digestive side effects, muscle loss and extra demand on the liver — and most "companion" supplements have thin evidence. We're building the one grounded in gut–liver science.

1 in 8
US adults have used a GLP-1
~70%
report GI side effects at some point
Gut–liver
the axis GLP-1s act through — and where we work

Why a probiotic — and why now

GLP-1 is a gut hormone. The medications amplify a signal your own gut cells produce — which is exactly why the gut–liver axis is the right place to support your body through treatment. Our probiotic is designed to work there.

🌱

Support gut comfort

Designed to support the gut barrier and microbiome during the digestive changes that come with GLP-1 treatment.

🛡️

Protect the liver

Supports the liver's antioxidant balance during rapid weight loss — through the gut–liver axis, where the liver is most influenced.

⚙️

Work with your own biology

Rather than adding another drug, our approach supports the natural gut signalling GLP-1 medications already rely on.

A probiotic capsule opening to reveal its active formulation

Full formulation details are proprietary and will be disclosed through peer-reviewed publication and our clinical program. This is not a substitute for your prescribed medication.7,10,11

Why the gut

GLP-1 starts in the gut. So does the support you need.

The GLP-1 hormone is released by cells in your gut, and travels via the gut–liver axis — the direct line between your gut and liver — to do its work. That same axis is where digestive side effects and liver demands play out during treatment.10,11

The gut sets the tone. GLP-1 medications slow the gut and shift the microbiome, which can drive nausea, constipation and bloating — supporting the gut barrier is an active research frontier.9,10
Weight loss asks a lot of the liver. As fat mobilises, the liver's antioxidant systems work harder. Supporting them through the gut–liver axis is a promising, evidence-led strategy.11
This is where we work. Rather than acting on the body from a distance, our probiotic works right at the source — in the gut — alongside your medication.10,11,12
Macro view of the gut–liver axis — gut and liver tissue in constant exchange
The gut–liver axis — where GLP-1 starts, and where we work.

Cutting-edge science

Recent discoveries, applied

Built on the last decade's breakthroughs in the gut–liver axis and engineered next-generation probiotics — a frontier only now becoming therapeutically real.10,11,12

Peer-reviewed foundations

Every mechanism we target is grounded in published, peer-reviewed research on the gut–liver axis and metabolic health.7,8,9

Clinical trial planned

We're preparing a clinical study to measure real effects on gut, liver and metabolic markers. We lead with evidence, not claims.

The evidence

Not another companion supplement. A probiotic we're putting through clinical study.

Most GLP-1 companion products ask you to trust them. We carry out trials to show they work.

Our founding team are PhD scientists and medical doctors working at the frontier of microbiome and gut–liver science — the same fields our approach is built on. We lead with evidence, measure honestly, and will publish what we find.

Salpie Nowinski
CEO · PhD
Salpie Nowinski

PhD Computational Biology, King's College London.

Max Mossner
CTO · PhD
Max Mossner

PhD Molecular Biology, Heidelberg University.

Gabriel Nowinski
CMO · MD
Gabriel Nowinski

Medical doctor; ran a Phase III trial.

Our team's published research appears in leading peer-reviewed journals, including Gut, Cancer Discovery and Nature Cancer.

Study 1 · Pharmacokinetics — planned

First, we prove the delivery.

Before claiming any effect, we measure whether the probiotic's active compound actually reaches the body — in both its free and its protected, vesicle-encapsulated form — where conventional oral antioxidants are broken down before they can work. This is the delivery question every supplement skips.

What we measure
Active compound in blood (free) Active compound (protected / encapsulated) Glutathione (GSH)
Study 2 · Effect Study — planned

Then, we prove the effect.

Once delivery is established, a second study measures what the probiotic actually does — first the gut-signalling mechanism that only an engineered living probiotic can drive, then the gut, liver and metabolic markers that matter to people on a GLP-1.

Mechanism signals — the probiotic doing its job
Native gut-signalling response Gut antioxidant balance
Gut, liver & metabolic markers
GI comfort / symptom scores Liver fat ALT (liver enzymes) Antioxidant / glutathione balance Lean mass retention Post-meal glucose

Studies are planned and not yet complete. Nothing here is a claim of clinical benefit — it is our commitment to measuring one. Full formulation details remain proprietary pending peer-reviewed publication.7,10,11

GLP-1 support: your questions, answered plainly

Straight answers to what people on Ozempic, Wegovy and Mounjaro most often search — grounded in current evidence, not marketing. This is general education, not medical advice; always speak to your prescriber about your own treatment.

What supplements should I take with Ozempic or Wegovy?
Many people on GLP-1 medications look for support with digestion, and with protecting muscle and liver health during rapid weight loss. Evidence-based basics include adequate protein, fibre, hydration and micronutrients — always check any supplement with your prescriber first. We're developing a next-generation probiotic companion designed to work through the gut–liver axis; it's in research and development and not yet available.
Why does Ozempic cause gut and digestive side effects?
GLP-1 medications slow stomach emptying and change gut motility, which can lead to nausea, constipation and bloating — especially early on or after a dose increase. These effects often settle over time. Supporting the gut barrier and microbiome is an area of active research. Speak to your doctor if side effects are severe or persistent.
Can a GLP-1 affect my liver?
GLP-1 medications are being studied for fatty liver disease, and many people see liver-fat improvements alongside weight loss. But rapid weight change also places demands on the liver's antioxidant and metabolic systems. Supporting the gut–liver axis during this period is a promising, actively-researched strategy. This is general education, not medical advice.
How do I protect muscle while losing weight on a GLP-1?
Rapid weight loss on GLP-1 medications can include loss of lean muscle. The evidence-based foundations are adequate protein intake and resistance exercise — discuss a plan with your clinician. Our probiotic is being developed to support metabolic and gut–liver health during weight loss, and is not a substitute for protein or exercise.
Is this a "natural Ozempic" or a replacement for my medication?
No. We don't make "natural Ozempic" claims. Our probiotic is a companion designed to support your gut and liver while you take your prescribed medication — not a replacement for it. Never stop or change a prescribed GLP-1 without talking to your doctor.

References

  1. Angulo P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with NAFLD. Gastroenterology 2015;149:389–397.
  2. Dulai PS, et al. Increased risk of mortality by fibrosis stage in NAFLD: systematic review and meta-analysis. Hepatology 2017;65:1557–1565.
  3. Vilar-Gomez E, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology 2015;149:367–378.
  4. Romero-Gómez M, et al. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol 2017;67:829–846.
  5. Trautwein C, et al. Hepatic fibrosis: concept to treatment. J Hepatol 2015;62(1 Suppl):S15–S24.
  6. Friedman SL, et al. Hepatic fibrosis 2022: unmet needs and a blueprint for the future. Hepatology 2022;75:473–488.
  7. Chen Z, et al. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med 2020;152:116–141.
  8. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of NAFLD. Metabolism 2016;65:1038–1048.
  9. Tilg H, Moschen AR. Evolution of inflammation in NAFLD: the multiple parallel hits hypothesis. Hepatology 2010;52:1836–1846.
  10. Albillos A, de Gottardi A, Rescigno M. The gut–liver axis in liver disease: pathophysiological basis for therapy. J Hepatol 2020;72:558–577.
  11. Aron-Wisnewsky J, et al. Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity? Gastroenterology 2020;158:1881–1898.
  12. Barra M, et al. Engineered probiotics for detection and treatment of inflammatory intestinal diseases. Front Bioeng Biotechnol 2020;8:265.
Daily GLP-1 Companion

Clinically-studied strains · a daily probiotic to support your gut & liver on a GLP-1

$49.50/month (est.)

Indicative early-access pricing · no payment taken today

  • Daily probiotic companion for people on GLP-1 medications
  • Designed to support gut comfort and the gut–liver axis
  • A medical food, taken under the guidance of your own physician
  • Priority place in our trial & early-access program

Reserve your place — we'll be in touch as the trial and launch approach

We'll email you about the trial and early access. No spam.

You're on the list ✓

We'll be in touch as our clinical trial and early-access program open. Thank you.

✓ Peer-reviewed science ✓ Clinical trial planned ✓ Works with your medication, not instead of it
Our mission

Pioneering next-generation probiotics for human and planetary health